🌍·4h agoIndustry
NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
Publisher
N
NervGen Pharma
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on nervgen.com
Leave the platform to read the original full article on the publisher site.
Source: NervGen Pharma
Scope: Industry
Related coverage
More related coverage
Allogene Therapeutics·3h ago
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Allogene Therapeutics·2d ago
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 202
Adaptive Biotechnologies·2d ago
Predicting T Cell Recognition: New Insights from Large-Scale Activation Data
A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell a...
eXoZymes·3d ago